Business Context and Reporting Period
Supernus Pharmaceuticals, Inc. filed this Form 8-K on June 22, 2016, to report a significant corporate event. The company is a Delaware corporation headquartered in Rockville, Maryland.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report focused on a specific non-financial event.
Material Changes
The primary material event reported is the issuance of a seventh patent by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR, the company's novel once-daily extended-release oxcarbazepine product.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) regarding the patent issuance. No financial guidance, management outlook, specific risk factors, or contingencies are detailed within the text of this Form 8-K.
Investor Verification Checklist
- Verify the scope and expiration date of the seventh USPTO patent for Oxtellar XR.
- Review the full text of the press release (Exhibit 99.1) for additional details on the patent's impact.
- Check subsequent filings for any financial impact or strategic shifts resulting from this intellectual property milestone.